Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589472232> ?p ?o ?g. }
- W2589472232 endingPage "783" @default.
- W2589472232 startingPage "783" @default.
- W2589472232 abstract "Abstract Abstract 783 Acute leukemia comprises several distinct subtypes. Apart from certain specific cytogenetic abnormalities associated with each of these subtypes, acquisition of additional somatic mutations is crucial to disease development. The present study is a comprehensive exploration of somatic mutations associated with several leukemia subtypes to catalog pattern of genetic changes associated with each category of leukemia. Moreover, the focus of the study is on identifying relapse specific mutations, thereby enabling us to understand the evolutionary relationship between clones present in primary leukemia and relapse. Whole exome sequencing was performed on 5–10 matched diagnosis, relapse and remission samples from each AML subclass characterized by either t(8;21), t(15;17), FLT3-ITD, MLL-PTD or normal cytogenetics (without FLT3-ITD and MLL-PTD) AML. Identification of somatic mutations and small indels was carried out using an automatic analysis pipeline which included 1) genome mapping using BWA, 2) calling for variant sites using SAMTOOLS, 3) annotation using ANNOVAR, and 4) filtering using Fisher exact test and sequence quality information. Candidate mutations were validated using Sanger sequencing and 5–10 nonsynonymous mutations per sample were found in each subtype, except the normal cytogenetics samples where 25–30 mutations were found, signifying a higher mutational load. In all subtypes, excluding APL, a large proportion of the mutations present at diagnosis were retained in relapse, suggesting a similar pattern of disease progression. In t(8;21) AML, we sequenced 10 paired diagnosis and relapse cases and identified 47 mutations shared between the two stages, while 10 mutations were diagnosis-specific and 35 were relapse-specific. Recurrent mutations were observed in KIT, TET2, TTN, and MGA genes in this subtype. In FLT3-ITD AML, 60 mutations in 50 different genes were found in 10 relapse and diagnosis cases. Amongst 50 mutations present at diagnosis, 38 were shared with the relapse samples. We observe recurrent mutations in several known genes including DNMT3A, WT1, RUNX1 and IDH1. In 5 cases of MLL-PTD AML, 42 genes were mutated, 24 of which were shared at both diagnosis and relapse. Similarly, a high prevalence of primary disease-associated mutations was also detected at relapse in normal cytogenetics AML, indicating persistence of disease clones during chemotherapy. In 8 cases of APL, 63 mutations in 61 genes occurred, with mutations in WT1 and PML appearing twice. Interestingly, while 4 cases shared at least one mutation between diagnosis and relapse stages, in the remaining 4 cases, the relapse resulted from independent clones. In acute lymphocytic leukemia exomes from 7 matched diagnosis and relapse pediatric cases, which should have done well but did poorly (normal cytogenetic or hyperdiploid cases), a similar rate of somatic mutations occurred as observed in myeloid malignancies. Interestingly, no non-synonymous mutations were detected in primary disease samples in 4 out of 7 cases, but each accumulated multiple mutations at relapse. The frequency of mutations in the newly identified mutant genes is currently being examined in a large cohort of diagnosis/relapse samples using custom target capture probes. We are integrating the exome sequencing data with gene expression and SNP array data for further selection of potential driver mutations. Pathway analysis is also being performed using the validated gene list from each leukemia subtype to explore affected biological processes. Finally, clonal evolution analysis using density-based clustering algorithm (DBSCAN) is being carried out to study the emergence of disease clones and its progression from primary disease to relapse stage. To our knowledge, this is the first large scale analysis of relapse leukemia in a variety of subtypes. Disclosures: Alpermann: MLL Munich Leukemia Laboratory: Employment. Haferlach: MLL Munich Leukemia Laboratory: Equity Ownership." @default.
- W2589472232 created "2017-03-03" @default.
- W2589472232 creator A5000444064 @default.
- W2589472232 creator A5008473414 @default.
- W2589472232 creator A5014821985 @default.
- W2589472232 creator A5015381826 @default.
- W2589472232 creator A5015705148 @default.
- W2589472232 creator A5016607292 @default.
- W2589472232 creator A5022501603 @default.
- W2589472232 creator A5024892590 @default.
- W2589472232 creator A5029332875 @default.
- W2589472232 creator A5031014013 @default.
- W2589472232 creator A5033443215 @default.
- W2589472232 creator A5034233071 @default.
- W2589472232 creator A5037454036 @default.
- W2589472232 creator A5039109076 @default.
- W2589472232 creator A5040001548 @default.
- W2589472232 creator A5040161241 @default.
- W2589472232 creator A5042588749 @default.
- W2589472232 creator A5043414993 @default.
- W2589472232 creator A5044229710 @default.
- W2589472232 creator A5051889915 @default.
- W2589472232 creator A5055601574 @default.
- W2589472232 creator A5058717098 @default.
- W2589472232 creator A5058755695 @default.
- W2589472232 creator A5061189755 @default.
- W2589472232 creator A5063094149 @default.
- W2589472232 creator A5068058602 @default.
- W2589472232 creator A5068363133 @default.
- W2589472232 creator A5069100961 @default.
- W2589472232 creator A5071954624 @default.
- W2589472232 creator A5072266288 @default.
- W2589472232 creator A5075981878 @default.
- W2589472232 creator A5079262854 @default.
- W2589472232 creator A5085821675 @default.
- W2589472232 creator A5086122797 @default.
- W2589472232 creator A5087689930 @default.
- W2589472232 date "2012-11-16" @default.
- W2589472232 modified "2023-09-29" @default.
- W2589472232 title "Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes" @default.
- W2589472232 doi "https://doi.org/10.1182/blood.v120.21.783.783" @default.
- W2589472232 hasPublicationYear "2012" @default.
- W2589472232 type Work @default.
- W2589472232 sameAs 2589472232 @default.
- W2589472232 citedByCount "0" @default.
- W2589472232 crossrefType "journal-article" @default.
- W2589472232 hasAuthorship W2589472232A5000444064 @default.
- W2589472232 hasAuthorship W2589472232A5008473414 @default.
- W2589472232 hasAuthorship W2589472232A5014821985 @default.
- W2589472232 hasAuthorship W2589472232A5015381826 @default.
- W2589472232 hasAuthorship W2589472232A5015705148 @default.
- W2589472232 hasAuthorship W2589472232A5016607292 @default.
- W2589472232 hasAuthorship W2589472232A5022501603 @default.
- W2589472232 hasAuthorship W2589472232A5024892590 @default.
- W2589472232 hasAuthorship W2589472232A5029332875 @default.
- W2589472232 hasAuthorship W2589472232A5031014013 @default.
- W2589472232 hasAuthorship W2589472232A5033443215 @default.
- W2589472232 hasAuthorship W2589472232A5034233071 @default.
- W2589472232 hasAuthorship W2589472232A5037454036 @default.
- W2589472232 hasAuthorship W2589472232A5039109076 @default.
- W2589472232 hasAuthorship W2589472232A5040001548 @default.
- W2589472232 hasAuthorship W2589472232A5040161241 @default.
- W2589472232 hasAuthorship W2589472232A5042588749 @default.
- W2589472232 hasAuthorship W2589472232A5043414993 @default.
- W2589472232 hasAuthorship W2589472232A5044229710 @default.
- W2589472232 hasAuthorship W2589472232A5051889915 @default.
- W2589472232 hasAuthorship W2589472232A5055601574 @default.
- W2589472232 hasAuthorship W2589472232A5058717098 @default.
- W2589472232 hasAuthorship W2589472232A5058755695 @default.
- W2589472232 hasAuthorship W2589472232A5061189755 @default.
- W2589472232 hasAuthorship W2589472232A5063094149 @default.
- W2589472232 hasAuthorship W2589472232A5068058602 @default.
- W2589472232 hasAuthorship W2589472232A5068363133 @default.
- W2589472232 hasAuthorship W2589472232A5069100961 @default.
- W2589472232 hasAuthorship W2589472232A5071954624 @default.
- W2589472232 hasAuthorship W2589472232A5072266288 @default.
- W2589472232 hasAuthorship W2589472232A5075981878 @default.
- W2589472232 hasAuthorship W2589472232A5079262854 @default.
- W2589472232 hasAuthorship W2589472232A5085821675 @default.
- W2589472232 hasAuthorship W2589472232A5086122797 @default.
- W2589472232 hasAuthorship W2589472232A5087689930 @default.
- W2589472232 hasConcept C104317684 @default.
- W2589472232 hasConcept C10590036 @default.
- W2589472232 hasConcept C119054055 @default.
- W2589472232 hasConcept C135763542 @default.
- W2589472232 hasConcept C141231307 @default.
- W2589472232 hasConcept C149904235 @default.
- W2589472232 hasConcept C153209595 @default.
- W2589472232 hasConcept C16671776 @default.
- W2589472232 hasConcept C174475383 @default.
- W2589472232 hasConcept C2778461978 @default.
- W2589472232 hasConcept C30481170 @default.
- W2589472232 hasConcept C501734568 @default.
- W2589472232 hasConcept C54355233 @default.
- W2589472232 hasConcept C75563809 @default.
- W2589472232 hasConcept C76818968 @default.
- W2589472232 hasConcept C86803240 @default.
- W2589472232 hasConceptScore W2589472232C104317684 @default.